Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep 25:3:78.
doi: 10.3389/fped.2015.00078. eCollection 2015.

The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome

Affiliations
Review

The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome

Pietro A A Canetta et al. Front Pediatr. .

Abstract

Adult-onset nephrotic syndrome (NS) differs from its pediatric counterpart in several important ways. Most importantly, NS in adults is more etiologically heterogeneous compared to children, and thus treatment approaches rely heavily on the histological diagnosis provided by renal biopsy. The evidence-based approach to treatment of adult NS has been critically examined by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines in glomerulonephritis, published in 2012. Here, we examine the strengths and limits of those guidelines and review recent work that expands the evidence-based approach.

Keywords: KDIGO guidelines; clinical practice guidelines; focal segmental glomerulosclerosis; minimal-change disease; nephrotic syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A suggested algorithm for the clinical approach to adult FSGS. *Note that KDIGO guidelines explicitly recommend against genetic testing. **Highlighted are some of the monogenic causes of FSGS more likely to be found in adults with genetic disease; see text and highlighted references for further discussion. NPHS2, Podocin; CD2AP, CD2-associated protein; ACTN4, α-actinin-4; INF2, inverted formin-2; TRPC6, transient receptor potential channel 6; WT1, Wilms tumor protein.

References

    1. Palmer SC, Sciancalepore M, Strippoli GF. Trial quality in nephrology: how are we measuring up? Am J Kidney Dis (2011) 58(3):335–7.10.1053/j.ajkd.2011.06.006 - DOI - PubMed
    1. Samuels JA, Molony DA. Randomized controlled trials in nephrology: state of the evidence and critiquing the evidence. Adv Chronic Kidney Dis (2012) 19(1):40–6.10.1053/j.ackd.2012.01.009 - DOI - PubMed
    1. Leaf DE, Appel GB, Radhakrishnan J. Glomerular disease: why is there a dearth of high quality clinical trials? Kidney Int (2010) 78(4):337–42.10.1038/ki.2010.156 - DOI - PubMed
    1. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol (2004) 15(2):411–9.10.1097/01.ASN.0000100125.21491.46 - DOI - PubMed
    1. Kidney Disease Improving Global Outcomes Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl (2012) 2(2):139–274.10.1038/kisup.2012 - DOI

LinkOut - more resources